对小分子激动剂识别和补充受体C3aRR激活的结构性见解
Jinuk Kim1,2, Saebom Ko1, Chulwon Choi1
1Department of Biological Sciences, Seoul National University, Seoul, 08826, Republic of Korea.
研究人员发现了补充成分3a受体 (C3aR) 的非活性和中间结构. 这揭示了C3aR激活的机制及其高基底活性,有助于治疗炎症疾病的开发.
科学领域:
- 结构生物学是结构生物学.
- 免疫学 免疫学 免疫学
- 生物化学 生物化学
背景情况:
- 补体系统对于天生的免疫力和炎症至关重要.
- 过敏毒素C3a受体 (C3aR) 通过G蛋白信号传递调解炎症反应.
- 了解C3aR的非活性状态和激活机制至关重要.
研究的目的:
- 为了确定无带C3aR.的冷-EM结构.
- 阐明C3aR.的形状变化和激活机制.
- 为C3aR的高基底活性提供分子基础.
主要方法:
- 低温电子显微镜 (cryo-EM) 用于确定C3aR结构.
- 在阿波,中间和活跃状态下对C3aR的结构分析.
- 与C3a.a.的C3aR-连接物相互作用的比较.
主要成果:
- 确定了不活跃的,无配体的C3aR.的冷-EM结构.
- 解决了C3aR与激素JR14a在中间和活性状态中的结构.
- 确定了JR14a与C3aR.的保守和特定相互作用.
- 揭示了对C3aR的结构格局和激活途径的洞察力.
结论:
- 该研究提供了非活性和中间C3aR构造的第一个结构.
- 结构洞察力解释了C3aR的高基底活动.
- 这些发现可能会指导对补充介导炎症性疾病的治疗方法的开发.
更多相关视频
06:56A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4
Published on: March 10, 2018
07:41A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
相关概念视频
Complement System
Drug-Receptor Interaction: Agonist
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
The Two-State Receptor Model
The binding affinity of a drug determines its interaction with...
Drug-Receptor Interactions
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
The direct-acting...
